All News

A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement from EntroGen.

Posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo highlighted trends in fertility care amid the turbulent landscape following the Dobbs decision.

Results of the monarchE study showed patients with hormone receptor–positive (HR+), HER2-negative (HER2–) high-risk, early breast cancer had greater benefit after 5 years when receiving adjuvant abemaciclib plus endocrine therapy vs endocrine therapy alone.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Posters presented at the American Society for Reproductive Medicine (ASRM) 2023 Scientific Congress & Expo addressed psychosocial symptoms and burdens faced by both embryologists and women of color with uterine fibroids.

Researchers found that heated tobacco products can reduce risks of exacerbations and exposure to toxic chemicals compared with combustible cigarettes in patients with chronic obstructive pulmonary disease (COPD).

Study investigators note their meta-analysis may be the first to demonstrate the importance of interventions to support adherence to adjuvant endocrine therapy for breast cancer.

Valerie Montgomery Rice, MD, FACOG, a distinguished infertility specialist, highlights the pivotal role of cultural humility, diversity, acknowledgment of historical injustices, and collective action in addressing disparities and fostering equitable access to health care.

Operational forecasting for patients who are eligible for gene therapies will be crucial for addressing the accessibility and affordability challenges with these agents, especially as more gene therapies are expected to enter the market in the next few years.

Anita Allen, PhD, professor of law and philosophy, University of Pennsylvania, discusses the impact of abortion regulations in different parts of the world on women's reproductive access and rights, as well as the repercussions of the Dobbs decision that overturned Roe v Wade.

Eric Donnenfeld, MD, from Ophthalmic Consultants of Long Island, discusses the importance of the Xdemvy FDA approval in treating patients with Demodex blepharitis.

Monica Bertagnolli, MD, fielded questions on hot-button issues during the long-delayed Senate hearing on her nomination to head the National Institutes of Health; Pfizer announces the list price for a 5-day course of its COVID-19 antiviral, nirmatrelvir/ritonavir (Paxlovid); a federal initiative is distributing funds to programs aiming to prevent drug overdoses in pregnant women.

Individuals aged up to 24 years living with HIV were likely to be satisfied with and would recommend telehealth services to their friends, a recent study found.

During a session at AMCP Nexus, panelists provided a historical overview on the 340B drug discount program, highlighting the intentions of the plan and the research gaps leading to misconceptions about the program and whether it’s working to lower costs for patients.

Speakers at AMCP Nexus 2023 reviewed the major changes resulting from the Inflation Reduction Act (IRA) that impacted Medicare in 2023 and previewed the new provisions being implemented in the coming years.

In this case study, a patient who had Duchenne muscular dystrophy (DMD) and received high-dose transgene therapy to upregulate cortical dystrophin subsequently developed acute respiratory distress syndrome and died.

In the aftermath of the Dobbs v Jackson Women’s Health Organization ruling, Anita Allen, PhD, highlights the challenges to abortion rights in the United States, emphasizing disparities faced by marginalized communities, outlining threats to reproductive health care, and calling for collective action and advocacy to defend constitutional privacy and uphold the dignity of all individuals.

Two posters presented at the American Society for Reproductive Medicine 2023 Scientific Congress & Expo address racial and socioeconomic factors that impact fertility and birth outcomes.

At AMCP Nexus, Evernorth's Aimee Tharaldson, PharmD, provided an overview of which medications the FDA has approved in 2023 and what’s to come in nononcology areas over the next 5 years, including new drugs for Alzheimer disease, hemophilia, and nonalcoholic steatohepatitis (NASH).

A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.

During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.

Amazon Prime air service is testing delivery of medication within an hour or ordering; Surging insurance costs are affecting 150 million Americans; Opponents of President Joe Biden's mental health care proposal argue potential rules could hinder access to quality care.

Experts in colorectal cancer (CRC) discussed the new health recommendations from the Network for Excellence in Health Innovations report and how they apply to the disparities in screening for CRC.

Panelists at AMCP Nexus provided an overview of the US obesity epidemic, dispelling myths about the causes of obesity, highlighting racial and economic disparities across the nation, and tackling how the managed care space can ensure accessibility to care for all patients.

"The racial and ethnic distribution of United States sperm donors differs significantly from the United States population, particularly for those of African American or Black descent,” Cassie Hobbs, MD, explained.

The results for a proposed aflibercept (Eylea) biosimilar and an accepted ranibizumab (Lucentis) biosimilar were presented at Euretina Congress 2023.

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests.